HER2

This publication has 14 references indexed in Scilit:

• A Study of the Value of p53, HER2, and Bcl-2 in the Prediction of Response to Doxorubicin and Paclitaxel as Single Agents in Metastatic Breast Cancer: A Companion Study to EORTC 10923
  Clinical Breast Cancer, 2000
• Herceptin (R) improves time to progression following chemotherapy in women with metastatic breast cancer
  European Journal Of Cancer, 1999
• Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
  Journal of Clinical Oncology, 1999
• Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
  British Journal of Cancer, 1999
• erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer
  JNCI Journal of the National Cancer Institute, 1998
• erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer
  JNCI Journal of the National Cancer Institute, 1998
• No significant predictive value of c- erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
  International Journal of Cancer, 1998
• p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
  Journal of Clinical Oncology, 1998
• ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
  Cancer Letters, 1994
• Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.
  Journal of Clinical Oncology, 1992